To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCAPI1471 | Arabinofuranosylcytosine Featured |
1-β-D-Arabinofuranosylcytosine, a cytosine analogue, inhibits DNA polymerases α, δ, and ε, and RNA polymerases resulting in suppression of DNA synthesis and repair. 1-β-D-Arabinofuranosylcytosine acts as an antimetabolic agent which is responsible for dam
More description
|
|
| DC4181 | Imatinib mesylate Featured |
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
More description
|
|
| DC7358 | APY29 Featured |
APY29 is an allosteric modulator of IRE1α; inhibits IRE1α autophosphorylation (IC50 = 280 nM) and activates IRE1α RNase activity.
More description
|
|
| DC70709 | PRL-295 Featured |
PRL295 is a small molecule Keap1-Nrf2 protein–protein interaction inhibitor.PRL295 binds to Keap1 in the cellular environment, disrupting its interaction with Nrf2, which leads to enhanced gene expression of the classical Nrf2 target NQO1 in cells and in vivo in the mouse liver.PRL-295 increases the thermostability of Keap1 in cell lysates and in live cells.PRL 295 decreased the levels of plasma alanine aminotransferase and aspartate aminotransferase upon acetaminophen-induced hepatic injury.
More description
|
|
| DC70801 | SRX3305 Featured |
SRX 3305 is a potent, triple BTK/PI3K/BRD4 inhibitor with IC50 of 6.5 nM, 15 nM, and 4 nM toward BTK, PI3Kɑ and PI3Kδ respectively, inhibits BRD4 BD1 and BD2 with IC50 of 77 and 95 nM.SRX3305 showed enhanced binding to the drug-resistant C481S mutant of BTK compared to SRX-3262 (IC50=9 uM and 25 uM, respectively).SRX3305 displayed cytotoxicity aginst MCL cell lines JeKo-1, Mino, Granta with IC50 of 58 nM, 1 nM, 1.1 uM, respectively.SRX3305 inhibited cell vbiability of JeKo-1 BTK C481S and Mino BTK C481S mutant cell lines with IC50 of 1 uM and 47 nM, respectively, with minimally toxic to healthy donor PBMCs.SRX3305 showed improved efficacy in MCL and Ibrutinib-resistant MCL cells, SRX3305 impacted gene expression, perturbs the cell cycle and promotes apoptosis in MCL.
More description
|
|
| DC26199 | DS-6051b Featured |
DS-6051b is a potent and selective ROS1 and TRK family inhibitor with IC50 of 0.207 nM, 0.622 nM and 0.980 nM against ROS1, NTRK1 and NTRK3. DS-6051b especially inhibits ROS1 G2032R and other crizotinib-resistant ROS1 mutants.
More description
|
|
| DC60417 | EN106 Featured |
EN106 is a potent inhibitor of FEMIB. EN106 targets FEM1B, an E3 ligase recently discovered as the critical component of the cellular response to reductive stress. By targeting C186 in FEM1B, EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1.
More description
|
|
| DC60416 | SUN59716 Featured |
SUN59716 is a key intermediate for chemical synthesis of cenobamate. This product has no formal name at the moment.
More description
|
|
| DC60414 | WAY-111543 Featured |
WAY-111543 is a bioactive chemical.
More description
|
|
| DC60411 | Boc-Val-Cit-PAB-PNP Featured |
Boc-Val-Cit-PAB-PNP is useful and cleavable linker for ADC (antibody drug conjugate) synthesis.
More description
|
|
| DC41150 | Fmoc-3VVD-OH Featured |
Fmoc-3VVD-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
|
| DC43617 | Moracin M Featured |
Moracin M is a phosphodiesterase-4 inhibitor isolated from Morus alba. Moracin M has anti-inflammatory activity. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo.
More description
|
|
| DC72751 | CT52923 Featured |
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
More description
|
|
| DC72304 | MMRi62 Featured |
MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.
More description
|
|
| DC60410 | CID91585 Featured |
2-(2,6-Dioxopiperidin-3-yl)phthalimidine (EM-12), a teratogenic Thalidomide analogue, is more active than Thalidomide and is much more stable for hydrolysis. 2-(2,6-Dioxopiperidin-3-yl)phthalimidine enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas.
More description
|
|
| DC70230 | AZ5576 Featured |
AZ5576 (AZ-5576) is a potent, selective CDK9 inhibitor with an IC 50 <5 nM, decreases phosphorlyation of Ser2-RNAPII in cells with an IC 50 of 96 nM.AZ5576 downregulated Mcl-1 and MYC protein abundance across multiple tested DLBCL cell lines and in primary DLBCL cells.MYC sensitizes DLBCL cells to AZ5576, genetic downregulation of MYC in U-2932 and OCI-LY19 cells resulted in diminished susceptibility to AZ5576.AZ5576 dose-dependently downregulated MYC transcription of a luciferase reporter containing multiple canonical MYC-MAX-binding sites, an effect more pronounced compared with multi-CDK inhibitor dinaciclib.AZ5576 restricts growth of xenografted DLBCL tumors in vivo.
More description
|
|
| DC72349 | CP-447697 Featured |
CP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation.
More description
|
|
| DC71909 | Exarafenib Featured |
Exarafenib (RAF/KIN_2787) is a potent, orally active pan-RAF inhibitor. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. Exarafenib can be used for cancer research.
More description
|
|
| DC60333 | BRD7586 Featured |
BRD-7586(BRD 7586) is a cell-permeable small molecule inhibitor of SpCas9 with EC50 of 6.2 µM and 5.7 µM in the eGFP-disruption and HiBiT-knock-in assays, respectively. BRD7586 specifically engages SpCas9 but not Cas12a in cells and enhances SpCas9 specificity at multiple loci.
More description
|
|
| DC50121 | GTPL-6019 Featured |
GTPL6019, also know nas IUN54940, DGFR Tyrosine Kinase Inhibitor III, is a PDGFR inhibitor with potential anticancer activity.
More description
|
|
| DC70423 | GA-017 Featured |
GA-017 (GA017) is a potent, selective, ATP-competitive LATS kinase (LATS1/2) inhibitor with IC50 of 4.10/3.92 nM, respectively, promotes cell growth.GA-017 increases the number and size of spheroids of various cell-types in both scaffold-based and scaffold-independent cultures.GA-017 also enhances the ex vivo formation of mouse intestinal organoids.GA-017 facilitates the growth of spheroids and organoids by stabilizing and translocating YAP/TAZ into the cell nucleus.GA-017 inhibits the Hippo pathway to promote YAP/TAZ stabilization and nuclear translocation.GA-017 induces expression of Hippo pathway-related genes such as ANKRD1, CYR61, and CTGF in SKOV3 cells in a time- and dose-dependent manner.GA-017 inhibited the activity of 16 kinases of the AGC family at 100 nM against a panel of 321 diverse kinases.The serine/threonine protein kinases LATS (LATS1/2) phosphorylate YAP/TAZ, key effectors of the growth- and proliferation-regulating Hippo signaling pathway.
More description
|
|
| DC46241 | GPR40/FFAR1 modulator 1(WUN55267) Featured |
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1).
More description
|
|
| DC60402 | Dov-Val-Dil-OH Featured |
Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin.
More description
|
|
| DC60401 | DL-AP-3 Featured |
DL-AP-3, or AP-3 is a Potent metabotropic glutamate receptor antagonist.
More description
|
|
| DC60400 | Gramicidin S Featured |
Gramicidin S is an anttiboitics. Gramicidin S reduces the cell number of planktonic cells within 20-40 min at a concentration of 40-80 μg/mL. Gramicidin S kills the cells of pre-grown biofilms at concentrations of 100-200 μg/mL, such that no re-growth is possible. The translocation of the peptide into the cell interior and its complexation with intracellular nucleotides, including the alarmon ppGpp, can explain its anti-biofilm effect. The successful treatment of persistently infected root canals of two volunteers confirms the high effectiveness of GS. The broad Gramicidin S activity towards resistant, biofilm-forming E. faecalis suggests its applications for approval in root canal medication.
More description
|
|
| DC60397 | 1-Methyl-3-amino-4-cyanopyrazole Featured |
|
|
| DC60395 | Meclozine Featured |
Meclozine is a histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.
More description
|
|
| DC60393 | T3 Featured |
|
|
| DC60392 | WEHL-04 Featured |
|
|
| DC60391 | WEHL-03 Featured |
|